MGX
HEALTHCAREMetagenomi, Inc. Common Stock
AI Insight
What's Moving MGX Today?
No stock-specific AI insight has been generated for MGX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.13$3.95
$1.20
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-2.29
Dividend Yield—
Dividend / Share—
ROE-49.0%
Profit Margin—
Debt / Equity—
Trading
Volume51K
Avg Volume (10D)—
Shares Outstanding37.6M
MGX News
25 articles- Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23Stock Titan·Jun 11, 2026
- Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strikeStock Titan·Jun 11, 2026
- Metagenomi CEO Jian Irish sells $4,854 in company stock By Investing.comInvesting.com Australia·Jun 10, 2026
- Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare ConferenceYahoo Finance·May 28, 2026
- Genome-editing firm Metagenomi CEO joins Jefferies June 4 fireside chatStock Titan·May 28, 2026
- Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their EstimatesYahoo Finance·May 14, 2026
- Metagenomi Highlights Q1 Progress on MGX-001 Gene TherapyTipRanks·May 12, 2026
- Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 12, 2026
- Metagenomi Therapeutics Reports Business Updates and First Quarter 2026 Financial ResultsYahoo Finance·May 11, 2026
- Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 7, 2026
- Metagenomi Therapeutics, Inc. Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Genome Editing EfficiencyGlobeNewswire Inc.·Apr 16, 2026
- Spotlight On 3 ASX Penny Stocks With Market Caps Under A$2BYahoo Finance·Apr 2, 2026
- Metagenomi Therapeutics (MGX) Reports Q4 Loss, Misses Revenue EstimatesYahoo Finance·Mar 5, 2026
- Metagenomi Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 5, 2026
- Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial ResultsYahoo Finance·Mar 5, 2026
- Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag EstimatesYahoo Finance·Feb 26, 2026
- Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare ConferenceYahoo Finance·Feb 23, 2026
- Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Feb 12, 2026
- Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate OutlookYahoo Finance·Jan 12, 2026
- Trainium3 UltraServers Now Available: Enabling Customers to Train and Deploy AI Models Faster at Lower CostYahoo Finance·Dec 2, 2025
- Amazon Launches New AI Chip While Teasing Future Tech Collaboration With NvidiaYahoo Finance·Dec 2, 2025
- Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature ConferenceYahoo Finance·Dec 1, 2025
- Metagenomi to Present at Jefferies Global Healthcare Conference in LondonYahoo Finance·Nov 17, 2025
- Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer dataBiopharmadive·Nov 12, 2025
- Metagenomi to Advance Hemophilia A Gene Therapy to Clinical TrialsYahoo Finance·Nov 11, 2025
All 25 articles loaded
Price Data
Open$1.24
Previous Close$1.24
Day High$1.29
Day Low$1.20
52 Week High$3.95
52 Week Low$1.13
52-Week Range
$1.13$3.95
$1.20
Fundamentals
Market Cap$47M
P/E Ratio—
EPS$-2.29
Dividend Yield—
Dividend / Share—
ROE-49.0%
Profit Margin—
Debt / Equity—
Trading
Volume51K
Avg Volume (10D)—
Shares Outstanding37.6M
About Metagenomi, Inc. Common Stock
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company is headquartered in Emeryville, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—